[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Rwanda\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":662},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,44,73,94,120,151,181,207,239,276,304,332,361,387,416,439,470,501,529,554,578,599,635],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100648551","heart-failure-self-care-education-in-rwanda-100648551",false,"NCT07722468","Heart Failure Self Care Education in Rwanda","Inclusion Criteria:\n\n* Participants living with heart failure followed at non-communicable disease clinics across three district hospitals (DHs) i- Butaro, Kirehe, and Rwinkwavu\n* Able to provide informed consent; for minors, able to provide assent with parent or caregiver consent.\n* Pediatric participants must be aged ≥10 years; consent will be obtained from a parent or caregiver, with age-appropriate assent from the child.\n\nExclusion Criteria:\n\n* Unable to provide informed consent","ALL","10 Years",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22],"NA","In Rwanda, patients with heart failure may have low health education about their condition. Heart failure care requires active patient involvement. Self-care of heart failure requires healthy lifestyle, attention to symptoms, proper action when new symptoms develop. However, many patients may choose to stop taking medications when they are feeling well, or disregard new symptoms when they develop and delaying care until their condition is more severe. Educating patients in self-care for heart failure can be achieved by clinical staff with the support of patient handbooks or flip books. Self-care education materials have been developed by the research team in Haiti and have been adapted for Rwanda.\n\nThis study will use a cluster, stepped wedge design. Patients are already in clusters based on their health facility. The order of implementation will be randomized by the cluster. The primary outcome is heart failure knowledge assessed pre- and post-intervention through a structured survey.",[25],"Heart Failure",[27,28,29,30],"Heart failure education","Group education sessions","District hospital clinics","Rwanda","NOT_YET_RECRUITING","2026-07-20",{"date":34,"type":35},"2026-07-23","ACTUAL",{"date":37,"type":19},"2026-09",{"date":39,"type":19},"2028-12",{"name":41,"class":42},"Boston Medical Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100641551","prospective-evaluation-of-an-ai-diagnostic-ultrasound-tool-for-fetal-weight-estimation-100641551","NCT07661433","Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation","Z 32503 - Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation","Inclusion Criteria:\n\n* 18 years of age or older\n* Viable intrauterine pregnancy\n* Delivery expected within one week of study procedures between 24 0\u002F7 and 42 6\u002F7 weeks, including participants with a scheduled induction or cesarean delivery on a known date, or those admitted in spontaneous labor\n* Ability and willingness to provide written informed consent\n* Willingness to comply with all study procedures\n\nExclusion Criteria:\n\n* Maternal body mass index ≥ 40 kg\u002Fm\\^2\n* Multiple gestation (i.e., twins or higher order)\n* Known major fetal malformation or anomaly\n* Any maternal condition (medical, psychological, or social) that, in the opinion of the study team, may interfere with study participation or data integrity.","FEMALE","18 Years",{"count":54,"type":19},1000,"OBSERVATIONAL","Purpose: The primary objective of this study is to assess the diagnostic accuracy of an AI-enabled ultrasound tool for estimating fetal weight Participants: 1,000 pregnant individuals Procedures (methods): This prospective diagnostic accuracy study will enroll 1,000 pregnant individuals within one week of anticipated delivery. At a single visit, each participant will undergo two ultrasound assessments: (1) standardized sweeps for AI analysis (performed by both specialist and nonspecialist users), (2) specialist-performed fetal biometry.",[58,59,60,61],"Fetal Weight","Pregnancy","Machine Learning","Pregnancy - Prenatal Testing","RECRUITING","2026-07-06",{"date":65,"type":35},"2026-07-08",{"date":67,"type":35},"2026-06-29",{"date":69,"type":19},"2026-12",{"name":71,"class":42},"University of North Carolina, Chapel Hill",5,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":20,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":72},"100497191","building-respiratory-support-in-east-africa-through-high-flow-versus-standard-flow-oxygen-evaluation-100497191","NCT05754034","Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation","BREATHE","Inclusion Criteria:\n\n* age\\>=18 years AND\n* admitted to a study site hospital within the 24 hours prior to screening AND\n* SpO2\\\u003C90% at time of first assessment OR\n* receiving oxygen at time of first assessment\n\nExclusion Criteria:\n\n* imminent death (high clinical suspicion of death within 24 hours of admission)\n* patient or caregiver refusal of study participation\n* history of chronic respiratory failure (SpO2\\\u003C90% or oxygen dependence for at least three months)\n* anatomical factors precluding the use of nasal cannula\n* intubation or non-invasive ventilation by the clinical team prior to screening for the trial\n* known hypoxemia at transferring facility for \\>48 hours\n* lack of availability of either SFO or HFO devices or supplies at the time of randomization.",{"count":81,"type":19},1600,[22],"Acute hypoxemia is common and deadly in resource variable settings. While studies in high income countries (HICs) have indicated a possible benefit to high flow oxygen as compared with standard flow oxygen, rigorous studies in low or lower middle income countries (LMICs) have not been performed. Studies in sepsis have demonstrated that interventions that improve outcomes in one context may actually be neutral or harmful in a different context.\n\nThe goal of this study is to test whether high flow oxygen results in better outcomes for hypoxemic adult patients, as compared with standard flow oxygen, in five LMIC hospitals. The main questions it aims to answer are:\n\n1. For hypoxemic adults in these LMIC study settings, does high flow oxygen or standard flow oxygen result in lower mortality?\n2. What are the facilitators and barriers to using high flow oxygen in these settings?\n3. Does high flow or standard flow oxygen use more oxygen?\n\nParticipants will be randomized to receive either high flow oxygen through a large nasal cannula, or to receive standard flow oxygen, through nasal cannulas, face masks, or non-rebreather masks. Researchers will compare the outcomes for the two groups, to see if one group of patients has better outcomes than the other.\n\nThe study will also examine how much oxygen is used by the two patient groups, as well as other factors relevant to the feasibility of implementation of high flow oxygen in these sites.",[85],"Acute Hypoxemia","2026-07-01",{"date":63,"type":35},{"date":89,"type":35},"2023-10-11",{"date":91,"type":19},"2026-12-31",{"name":93,"class":42},"Beth Israel Deaconess Medical Center",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100644369","breast-and-cervical-cancer-stigma-in-rwanda-100644369","NCT07663006","Breast and Cervical Cancer Stigma in Rwanda","Assessing Breast and Cervical Cancer Stigma and Piloting a Mitigating Intervention in Rwanda","Aim 1 Inclusion and Exclusion Criteria Aim 1 Interviews and Surveys\n\nIndividual interviews and surveys:\n\nPotential patients will be identified by the clinical team from physical and electronic registries of patients. Potential participants will be screened for eligibility by the study research assistant.\n\nInclusion Criteria\n\n* Patients with pathologically confirmed breast or cervical cancer\n* Patients receiving treatment at BCCOE during the study period\n* Age 18 and over\n* Ability to provide informed consent\n* Ability to participate in interview or surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation.\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment\n\nInterpersonal interviews and surveys:\n\nCaregivers of the potential patients will be identified from the potential patients. Potential patients will be identified by the clinical team from physical and electronic registries of patients. Potential participants will be screened for eligibility by the study research assistant.\n\nInclusion Criteria\n\n* Caregiver (including spouses, children, family members or other individuals as designated by patients) of patients with pathologically confirmed breast or cervical cancer who are actively receiving treatment at BCCOE during the study period\n* Age 18 and over\n* Ability to provide informed consent\n* Ability to participate in interview or surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation.\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment\n\nInstitutional Focus group:\n\nAn official participation letter will be sent from BL2TH to leaders of the preselected facilities. Interested participants will be encouraged to contact the study team. Potential participants will be invited by their hospital\u002Fcenter leadership and screened for eligibility by the study research assistant.\n\nInclusion Criteria\n\n* Healthcare Worker\n* Working in a preselected health center, district hospital, provincial hospital in the Northern Province\n* Age 18 or older\n* Ability to provide informed consent\n* Ability to participate in interview or surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation.\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment\n\nInstitutional surveys:\n\nFormal participation invitation will be sent to the Rwanda Medical and Dental Council, National Council of Nurses and Midwives, and the Rwanda Allied Health Professions Council. Potential participants will be screened for eligibility electronically and informed consent obtained electronically.\n\nInclusion Criteria\n\n* Healthcare Worker\n* Registered with relevant professional organization in Rwanda\n* Age 18 or older\n* Ability to provide informed consent\n* Ability to participate in surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation.\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment\n\nAim 2 Inclusion and Exclusion Criteria Aim 2 Intervention pilot (patient, caregivers and community health workers)\n\nPatient and Caregiver Pilot:\n\nInclusion Criteria\n\n* Patients with pathologically confirmed breast cancer who are actively receiving curative-intent treatment at BCCOE during the study period and a designated caregiver\n* Patients getting systemic neoadjuvant chemotherapy who are expected in the clinic on a 3-week cycle\n* Patients who have at least 4 cycles of therapy remaining\n* Age 18 and over\n* Ability to provide informed consent\n* Ability to participate in pilot, interview, and surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation.\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women Note: Determination of ability to consent will be made by trained study staff prior to enrollment\n\nCommunity Health Worker Pilot:\n\nInclusion Criteria\n\n* Community Health Worker registered with relevant healthcare facilities in Northern Rwanda\n* Age 18 or older\n* Willing to engage in activities related to breast and cervical cancer and to support survivors\n* Ability to provide informed consent\n* Ability to participate in pilot, interview, and surveys in English or Kinyarwanda\n\nExclusion Criteria\n\n* Unwilling or Unable to consent to participation\n* Unable to comprehend study language (Kinyarwanda or English)\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women",{"count":102,"type":19},1116,[22],"This study aims to assess breast and cervical cancer stigma and pilot a multi-modal intervention to mitigate stigma among patients, caregivers, and community health workers in Rwanda. The elements include resilience training (patient), support group (caregivers), or exposure to survivors by video and in-person (patient, caregivers, and community health workers), and educational curriculum (community health workers).",[106,107],"Breast Cancer","Cervical Cancer",[106,107,109],"Cancer Stigma","2026-06-22",{"date":112,"type":35},"2026-06-23",{"date":114,"type":19},"2026-11-01",{"date":116,"type":19},"2029-12-01",{"name":118,"class":42},"Dana-Farber Cancer Institute",2,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100642528","smart-discharges-for-older-children-100642528","NCT07629154","Smart Discharges for Older Children","Smart Discharges for Older Children: A Cohort Study to Develop Prognostic Algorithms for Post-discharge Readmission and Mortality Among Children Over 5 Years of Age","Inclusion Criteria:\n\n* Age between 0 and 16 years admitted to pediatric ward of hospital for proven or suspected infection\n* Provide informed consent\n* Ability to provide contact information (phone number or address) for phone or in-person follow-up\n\nExclusion Criteria:\n\n* Child lives outside of the catchment area of a study site\n* Admitted for elective procedures, trauma, or short-term observation\n* Language barriers","5 Years","16 Years",{"count":130,"type":19},4000,"This study is an observational multi-country cohort study that aims to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after they are discharged in East Africa.\n\nIn low- and middle-income countries, about 5% of children discharged after hospitalization for sepsis will die in the weeks after returning home. Doctors and parents are often unaware of this period of vulnerability and are poorly equipped to identify or handle this critical situation. This project builds on past work that developed and evaluated models and the Smart Discharges program to predict, during hospitalization, an individual child's risk of recurrent illness and mortality, as well as to provide additional post-discharge support to at-risk children.\n\nParticipants will be enrolled from facilities once they are admitted, collecting clinical and social variables. They will then be followed until 6 months post-discharge to understand what happens to them after they return home. This data will be evaluated to identify which variables collected at facilities can be predictive of mortality and recurrent illness after discharge.",[133],"Sepsis",[135,136,137,138,139,140],"pediatrics","sepsis","risk-prediction","critical care","post-discharge","patient discharge","2026-06-10",{"date":143,"type":35},"2026-06-15",{"date":145,"type":35},"2024-01-02",{"date":147,"type":19},"2027-04",{"name":149,"class":42},"University of British Columbia",7,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":158,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":20,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100578508","strategies-to-decentralize-breast-ultrasound-in-rwanda-100578508","NCT06812208","Strategies to Decentralize Breast Ultrasound in Rwanda","Implementation Strategies to Decentralize Breast Ultrasound Services and Facilitate Timely Breast Cancer Diagnoses in Rwanda","Enrollment in this cluster randomized clinical trial will occur at the health facility level.\n\nInclusion Criteria:\n\n1. District hospital in Rwanda;\n2. Already implementing the Women's Cancer Early Detection Program in their districts (i.e. clinicians in health centers and hospitals in the district have received the nationally-sponsored trainings in breast cancer early detection and cervical cancer screening);\n3. Already using the WCEDP electronic medical record in health centers and the district hospital, or prepared to start using it.\n\nExclusion Criteria:\n\n1\\. Already providing routine breast ultrasound in the district hospital.",true,{"count":160,"type":19},1792,[22],"Diagnosing breast cancer early is critical to reduce preventable breast cancer deaths in sub-Saharan Africa. This can be done in part through increasing patients' access to breast ultrasound, which is essential for evaluating breast masses. However, ultrasound is typically provided only by radiologists at urban referral hospitals. Training clinicians at rural district hospitals who are not radiologists could increase patients' access to breast ultrasound, but strategies to support and supervise these clinicians and ensure they are providing high-quality ultrasound services has not been studied.\n\nThis project will examine the effectiveness and cost of two strategies for training non-radiologist clinicians to perform breast ultrasound in Rwandan district hospitals.",[106,164,165],"Early Detection of Cancer","Ultrasonography",[167,168,169,170,171,30],"breast ultrasound","implementation strategies","low and middle income countries","breast cancer early detection","teleultrasound","2026-06-01",{"date":174,"type":35},"2026-06-02",{"date":176,"type":19},"2027-01",{"date":178,"type":19},"2029-11-30",{"name":180,"class":42},"Brigham and Women's Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":20,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},"100636185","adjuvant-endocrine-therapy-adherence-intervention-pilot-in-rwanda-100636185","NCT07562399","Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda","Piloting an Intervention to Improve Adjuvant Endocrine Therapy Adherence in Patients With Breast Cancer in Rwanda","Inclusion Criteria:\n\n* Female patients\n* Age 18 or older\n* Pathologic confirmation of ER-positive breast cancer\n* Clinical or radiographic confirmation of disease localized to the breast and regional lymph nodes\n* Within 6-36 months of starting AET\n* Have a cellphone capable of receiving text messages.\n* Are currently receiving AET at Butaro or satellite clinics.\n\nExclusion Criteria:\n\n* Unwilling\u002FUnable to participate\n* Unable to comprehend study languages (English or Kinyarwanda)\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women",{"count":189,"type":19},224,[22],"This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.",[193,106],"Medication Adherence",[195,196,197],"breast cancer","medication adherence","ER-positive breast cancer","2026-05-18",{"date":200,"type":35},"2026-05-20",{"date":202,"type":19},"2026-09-20",{"date":204,"type":19},"2028-12-31",{"name":118,"class":42},4,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":51,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":20,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":43},"100622999","feasibility-study-comparing-one-vs-two-probes-for-ta-among-cervical-cancer-screen-positive-wlwh-in-c1001p-cs5-rwanda-100622999","NCT07390916","Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda","Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV","Inclusion Criteria:\n\n1. 25-49 years old\n2. Living with HIV\n\nInclusion criteria specific to the feasibility study\n\n1. Intact cervix\n2. Willing to return to facility at 6 months\n3. Willing and able to provide informed consent\n4. Positive hrHPV or VIA test within 3 months of enrollment\n5. Type 1 transformation zone (TZ1)\n6. Thermal ablation eligible\n\nExclusion Criteria:\n\n1. Screened for cervical cancer outside of study in last 6 months\n2. Currently pregnant or less than 6 weeks postpartum\n3. Prior diagnosis of cervical cancer\n4. A history of treatment for cervical precancer\n5. Total hysterectomy\n6. Currently receiving treatment for any cancer\n7. Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study\n8. Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled","25 Years","49 Years",{"count":217,"type":19},300,[22],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. This is even more important at a time when Rwanda has launched a National Cervical Cancer Screening Program (NCCSP) with human papillomavirus (HPV) testing and treatment, mainly using TA with unknown outcomes. Therefore, we will conduct a feasibility study (C1001P-CS5) among 300 Rwandan WLWH to provide evidence needed to launch a future effectiveness study. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030. Rwanda hopes to achieve this goal early, in 2027 under Mission 2027.",[221,222,223],"HIV (Human Immunodeficiency Virus)","HPV","Cervical Precancer",[225,226,227,228,229],"HIV","Cervical cancer screening","Treatment of Cervical Precancer","Thermal ablation","Human papillomavirus","2026-04-24",{"date":232,"type":35},"2026-04-29",{"date":234,"type":19},"2026-05-31",{"date":236,"type":19},"2028-05-31",{"name":238,"class":42},"Fred Hutchinson Cancer Center",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":158,"sex":15,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":20,"phases":250,"briefSummary":252,"conditions":253,"keywords":261,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":43},"100635079","phase-1-safety-and-pk-of-mmv371-lai-in-healthy-adults-and-adolescents-in-rwanda-100635079","NCT07548021","Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda","A Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 Long-Acting Injection in Healthy Adults and Adolescents in Rwanda","Inclusion Criteria:\n\n1. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For adolescents, written assent and parental\u002Flegal authorized representative (LAR) consent must be obtained, in accordance with local regulations.\n2. Able to provide proof of identity to the satisfaction of the Investigator or delegate completing the enrolment process\n3. Able and willing to communicate effectively and comply with all study procedures for the duration of the study (including IM injections, safety assessments, blood sampling, malaria monitoring, follow-up visits)\n4. Living within local jurisdiction of trial site(s) and available for the duration of the trial Demographics and Contraception\n5. Male or female participants aged 12 to 50 years inclusive at the time of signing informed consent\u002Fassent.\n6. WOCBP must be non-pregnant and non-lactating, confirmed by a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test at admission, prior to IMP administration. WOCBP must agree to use, at minimum, acceptable contraception methods, as defined by the Clinical Trials Coordination Group (CTCG) guidance, from 21 days prior to study Day 1 through the End-of Study visit (Week 24) (Clinical Trials Coordination Group (CTCG), 2024).\n7. Post-menopausal participants must have menopause confirmed at screening, defined as a follicle-stimulating hormone (FSH) level ≥ 25.8 mIU\u002FmL Baseline Characteristics\n8. Healthy volunteers, as determined by:\n\n   physical examination Vital signs 12 lead ECG absence of malaria symptoms at baseline (note: a positive blood smear without malaria symptoms at baseline is not exclusionary) Hematology, biochemistry or urinalysis results at screening or at the admission visit (Day -1) that are within the standard clinically acceptable laboratory ranges defined for this study (See section 10.7 Appendix 7)\n9. For adults (18-50 years): Body Weight ≥45 kg at screening\n10. For adolescents (12-17 years): body weight ≥35 kg at screening Participant-reported outcomes (PROs)\n11. Able to understand and complete participant-reported outcome assessments (e.g., injection-site reaction diary and injection acceptability assessments), either independently or with assistance, in a language and format approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Medical Conditions\n\n  1. Positive malaria blood smear microscopy at the Admission visit (Day -1).\n  2. Acute febrile illness within 96 hours prior to enrolment or within 96h prior to Day 1.\n  3. Serious adverse reaction or clinically significant hypersensitivity to drugs or formulation excipients used in the study: artemether-lumefantrine (Coartem® or generic formulations) and atovaquone (Wellvone®\u002FMepron® and\u002For Malarone® or their generics).\n  4. Any history of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrolment that, in the opinion of the Investigator, has a reasonable risk of recurrence during the trial.\n  5. Any current uncontrolled medical or psychiatric condition, or substance abuse problems that, in the opinion of the Investigator, would make it unlikely for the participant to comply with the protocol, may interfere with study assessments, or could jeopardize the safety of the participant.\n  6. Evidence of clinically significant neurologic, cardiac, gastro-intestinal, dermatologic, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, haematological, oncologic, or renal disease, as determined by medical history, physical examination, and\u002For laboratory evaluations, including urinalysis.\n  7. History of a bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or a history of significant bruising with blood draws.\n  8. Known or documented sickle cell disease by history. Note: known sickle cell trait is not exclusionary.\n  9. Presence of sinus node dysfunction; clinically significant PR interval prolongation (\\>220 msec); intermittent second- or third-degree atrioventricular block; complete bundle branch block; sustained cardiac arrhythmias including, but not limited to, atrial fibrillation or supraventricular tachycardia; any symptomatic arrhythmia except isolated extrasystoles; abnormal T wave morphology that may interfere with QT\u002FQTc assessment; or QTcF \\>450 msec (adults and adolescents).\n\n     Physical Examination\n  10. Participants who do not have adequate venous access for multiple venipunctures or cannulation, as assessed by the Investigator or delegate at screening.\n  11. Participants with tattoos, scars or other clinically significant dermatological lesions or conditions overlying the deltoid, gluteal, or vastus lateralis region that, in the opinion of the Investigator, may interfere with injection site assessments.\n\n      Diagnostic Assessments\n  12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab). or human immunodeficiency virus (HIV) 1 and 2 antibody results.\n\n      Prior Study Participation\n  13. Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1, or within fewer than 5 elimination half-lives prior to Day 1 (whichever is longer). Note: Past, current, or planned participation in non-interventional (observational) studies is not exclusionary.\n  14. Participants who are currently enrolled in another interventional clinical trial within 90 days prior to Day 1, or who intend to participate in another interventional clinical trial during their participation in this study.\n  15. Donation of blood or plasma, or loss of more than 400 mL of blood, within 90 days prior to Day 1.\n\n      Prior and Concomitant Medication or Vaccine\n  16. Use of antimalarial chemoprevention or treatment, and\u002For antibiotics with known antimalarial activity (see Section 10.6 Appendix 6), within 6 weeks or fewer than 5 elimination half-lives prior to Screening (whichever is longer).\n  17. Current or recent (within 30 days prior to Day 1) use of rifampin\u002Frifampicin, rifabutin, tetracycline, or indinavir due to potential drug-drug interaction risk with atovaquone.\n  18. Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \\>10 mg\u002Fday) or other immunosuppressive drugs within 30 days prior to Day 1.\n  19. Receipt of a live attenuated vaccine within 4 weeks or an inactivated vaccine within 2 weeks prior to Day 1.\n  20. Receipt or planned receipt during the study of any doses of a malaria vaccine (investigational or registered, such as RTS, S\u002FAS01 or R21\u002FMatrix-M) or monoclonal antibodies (mAb) directed against Plasmodium falciparum.\n  21. Receipt of immunoglobulins and\u002For blood products within the past 6 months. Lifestyle Characteristics\n  22. History or medical, occupational, or family problems related to alcohol or illicit drug use within the past 12 months that, in the opinion of the Investigator, may interfere with study participation, compliance, or participant safety.\n\n      Other Exclusion Criteria\n  23. Participants who are, or are immediate family members of, study site staff or Sponsor employees involved in the conduct of the study.\n  24. Any other condition or circumstance that, in the opinion of the Investigator, would make the participant unsuitable for the study or could compromise participant safety or data integrity.","12 Years","50 Years",{"count":249,"type":19},80,[251],"PHASE1","This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda. MMV371 has been designed as a long acting injection (LAI). Protective efficacy (PE) will be assessed as an exploratory endpoint. Protective efficacy measures if participants are protected from becoming ill with malaria whilst the MMV371 is still present in their body. The study will enroll approximately 80 healthy male and female participants, aged 12 to 50 years. Before starting the study participants will be given a standard approved course of artemether lumifantrine (AL) to clear any malaria infection they have. Once the AL course has been completed the study drug will be given by injection in the muscle of the upper arm, the side of the thigh, or the hip. Three out of four participants will receive MMV371 and 1 in four participants will receive placebo. Placebo is a dummy medicine. All participants have an equal chance of being assigned to receive the injection in the upper arm, outer thigh or hip. Neither the participants nor the researchers treating the participants will know who received MMV371 or placebo until after the study is completed.\n\nKey study features include:\n\n* Study duration for each participant: up to 7 months\n* MMV371 or placebo given: a single intramuscular (IM) injection\n* Visit schedule: Participants will remain in-clinic on Days -1-2 (2 overnight stays), followed by 15 follow-up visits: Day 4, then weekly for 1 month, and subsequently every 2 weeks until the End-of-Study (EoS) visit at Week 24.\n\nThese frequent visits are necessary to monitor safety, the levels of MMV371 in the body, and to perform malaria detection testing until EoS (Week 24).",[254,255,256,257,258,259,260],"Malaria (Plasmodium Falciparum)","Malaria Falciparum","Malaria Infection","Malaria Prophylaxis","Malaria Prevention","Malaria","Malaria Parasitaemia",[262,263,264,265,266,267],"malaria prevention","malaria prophylaxis","malaria falciparum","Malaria infection","Malaria Long-Acting Injectable","Long-Acting Injectable","2026-04-17",{"date":270,"type":35},"2026-04-23",{"date":37,"type":19},{"date":273,"type":19},"2028-03",{"name":275,"class":42},"Medicines for Malaria Venture",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":158,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":20,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":43},"100588471","rwanda-digital-dashboard-hybrid-type-3-implementation-study-100588471","NCT06941831","Rwanda Digital Dashboard Hybrid Type 3 Implementation Study","Testing an mHealth Digital Dashboard to Improve Quality of Delivery of Evidence-based Interventions That Promote Family Mental Health and Functioning in Rwanda: A Hybrid Type 3 Study","Inclusion Criteria:\n\n* Household inclusion criteria: Participants must be the primary caregiver to a child between birth and 36 months. Caregivers must live in the same household as the child and must be the child's legal guardian. Legal guardians may be parents, aunts, uncles, grandparents, or foster parents. Participants must be categorized as Ubudehe 1 under the socio-economic categorization of households from LODA.\n* Government Official inclusion criteria: Government officials must be located at the Village, Cell, Sector and\u002For District level and must participate in the 1-day ECD training. Government officials must also agree to participate in the PLAY Collaborative activities throughout the course of program delivery.\n* IZU interventionist inclusion criteria: IZUs must be a part of the Inshuti z'Umuryango\u002FFriends of the Family program, must be over the age of 18, and must be literate in Kinyarwanda.\n* Cell Level IZU Mentor inclusion criteria: Cell Level IZU Coordinators must be situated at the Cell Level and able to supervise at least 12 IZU interventionists, must be over 18 years of age, and must be literate in Kinyarwanda.\n\nExclusion Criteria:\n\n* Household exclusion criteria: Potential participants will be excluded if they do not meet the inclusion criteria above, are experiencing an active crisis (e.g., psychosis), or have severe cognitive impairments which preclude their ability to speak to the research questions\u002Fassessments under scrutiny.\n* Government Official exclusion criteria: Government officials will be excluded from participation in the PLAY Collaborative if they are not located at the Cell, Sector or District level and if they are unable to meet the demands of participation in the PLAY Collaborative.\n* IZU interventionist exclusion criteria: IZUs will be excluded from participation if they do not meet the inclusion criteria above and if they are unable to meet the demands of delivering the Sugira Muryango program.\n* Cell Level IZU Mentor exclusion criteria: Cell Level IZU Coordinators will be excluded if they do not meet the inclusion criteria above or are unable to meet the demands of supporting the delivery of the Sugira Muryango program.",{"count":284,"type":19},1810,[22],"Mental disorders are leading causes of the health-related burden globally, and in Rwanda the intergenerational mental health consequences of the 1994 Genocide against the Tutsi persist and are further compounded by poverty, such that recent studies have found 20% of the Rwandan population has one or more mental disorders.\n\nThe Research Program on Children and Adversity (RPCA) has expanded its evidence-based home-visiting Sugira Muryango (SM) in Rwanda. The current study aims to assess a digitally enhanced delivery of Sugira Muryango to meet the needs of the Government of Rwanda in expanding the mental health and social services infrastructure.\n\nThe proposed research will test the feasibility, acceptability and impact of a technology-enabled service delivery model using a digital tool that streamlines data collection, improves visibility of key program performance metrics, and serves as a resource for learning materials that can be used for continuous learning and training of a non-specialized workforce that is delivering an evidence-based intervention that improves caregiver mental health and family functioning. What the team learn from technology-supported delivery of Sugira Muryango - an evidence-based, trauma-informed, family-based behavioral intervention in Rwanda - can be used to improve the efficiency, effectiveness, and scalability of evidence-based mental health services in Rwanda and globally.",[288,289,290,291,292,293,294],"IPV","Mental Health","Discipline Practices","Quality Assurance","Provider Confidence","Provider Skill","Quality of Life","2026-03-24",{"date":297,"type":35},"2026-03-27",{"date":299,"type":35},"2025-01-30",{"date":301,"type":19},"2029-05-31",{"name":303,"class":42},"Boston College",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":20,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":43},"100628345","bag-cpap-vs-standard-oxygen-therapy-in-acute-hypoxemic-respiratory-failure-100628345","NCT07460427","Bag CPAP vs Standard Oxygen Therapy in Acute Hypoxemic Respiratory Failure","Bag CPAP Versus Standard Oxygen Care for the Management of Acute Hypoxemic Respiratory Failure in Adults: A Randomized Controlled Trial","BAGCPAP-R","1. Inclusion criteria\n\n   All patients aged 18 years or older will be included in the study if they meet the following criteria:\n   * De novo acute respiratory distress, characterized by the presence of dyspnea at rest, the use of accessory muscles for breathing, or a respiratory rate of 25 cycles per minute or more.\n   * Hypoxemia, defined as a SpO2\u002FFiO2 ratio less than 315 or a PaO2\u002FFiO2 ratio less than 300 mmHg (if arterial blood gas is available) despite an oxygen therapy of 6 L\u002Fmin. FiO2 will be estimated by the rule of 3% (Coudroy formula)(18,22). SpO2 should be less than 98% when assessing the SpO2\u002FFiO2 ratio.\n2. Exclusion criteria\n\nPatients with one of the following criteria will be excluded from the study:\n\n* Absolute contraindications to CPAP: patient's refusal, uncontrollable vomiting, upper gastrointestinal bleeding, open or sucking chest wound, pneumothorax not drained, craniofacial trauma, severe burns to the face, severe upper airway obstruction, traumatic tetraplegia at the initial stage, tracheostomy.\n* Moderate to massive pleural effusion not drained\n* Cardiac arrest, severe ventricular arrhythmias, and shock defined as the need for vasopressor support (adrenaline, noradrenaline, or dopamine)\n* Altered level of consciousness (GCS below 12), repetitive convulsions, or status epilepticus\n* Do not intubate or resuscitate order before the inclusion in the study\n* Refusal to participate, already included in the study, enrollment in another interventional trial on acute respiratory failure",{"count":313,"type":19},250,[22],"Acute Hypoxemic Respiratory Failure (AHRF) is one of the prevalent causes of admission around the world and is associated with high mortality in resource-limited settings. Limited access to invasive mechanical ventilation is among the contributing factors to poor outcomes. The Bag CPAP may be useful in reducing the need for intubation and therefore mortality in patients with AHRF but data are lacking. This study aims to determine whether the Bag CPAP compared to standard oxygen care, could reduce the percentage of patients with criteria for intubation in patients with AHRF.\n\nThis is a prospective randomized, open-label, controlled trial in which patients presenting at the emergency room in Rwanda will be randomly assigned to receive standard oxygen therapy or Bag CPAP. The primary endpoint is the percentage of patients with criteria for intubation at day 7. Secondary endpoints include the tolerance of the Bag CPAP, overall 28-day mortality rate, mortality rate of intubated patients on mechanical ventilation at day 28, percentage of patients intubated at 28 days, ventilator-free days at day 28, interval between the initiation of treatment and the onset of intubation criteria, the interval between the time when criteria for intubation are met and intubation, organ failure-free days at day 7 and length of hospital stay.",[317],"Acute Hypoxemic Respiratory Failure",[319,320,321,322],"CPAP","Randomized controlled trial","Respiratory Failure","Low resource setting","2026-03-16",{"date":325,"type":35},"2026-03-19",{"date":327,"type":19},"2026-04-20",{"date":329,"type":19},"2027-03-20",{"name":331,"class":42},"Prof RWABIHAMA Jean Paul",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":158,"sex":15,"minAge":127,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":20,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":43},"100627248","tetanus-antibody-detection-in-saliva-study-100627248","NCT07446166","TETANUS Antibody Detection in Saliva Study","Development of Novel Diagnostics That Use Point-of-care Lateral Flow Testing Technology for Non-invasive, Individual Assessment of Antibody Protection to Tetanus and Vaccine Need","TETANUS","Inclusion Criteria:\n\n* Able and willing to provide informed consent to take part in the study; either directly or from a parent\u002Fguardian, where appropriate\n* \\[Group A\\] Aged 5-10 years inclusive, and determined as healthy by a member of the study team\n* \\[Group B\\] Aged 18-25yrs inclusive, and determined as healthy by a member of the study team\n* \\[Group C\\] Currently pregnant at any stage of pregnancy, prior to receipt of a tetanus booster vaccine in pregnancy, and determined as healthy by a member of the study team and safe to provide a blood sample\n* \\[Group D\\] Adults aged 18-45 years with one or more of the medical conditions that may affect antibody response to vaccination.\n\nExclusion Criteria:\n\n* Participants or parents\u002Fguardians unwilling or unable to provide informed consent to take part\n* Unwilling or unable to comply with study procedures\n* Have a bleeding disorder deemed significant by study doctor\n* \\[Groups A, B and C only\\] Any health condition which, in the opinion of a study physician which could\n\n  1. mean blood sampling has the potential for harm and\u002For\n  2. affect immune response to a vaccine for example known\u002Fsuspected impairment of immune function (with the exception of Group D)","45 Years",{"count":342,"type":19},390,[22],"This study aims to design, develop and optimise a non-invasive, saliva sample-based point-of-care lateral flow test for use in low and middle income settings that can return a qualitative result on whether an individual has or has not immunity to tetanus within 10-15mins. If successful, this approach would not require blood sampling or laboratory facilities, empower personalised decision making on vaccine needs and support the development of population level data-driven public health policies.",[346],"Tetanus",[348,349,350,351],"point-of-care","Lateral Flow Test","Rapid Diagnostic","Immune Diagnostic","2026-02-25",{"date":354,"type":35},"2026-03-03",{"date":356,"type":19},"2026-02-01",{"date":358,"type":19},"2028-02-01",{"name":360,"class":42},"University of Birmingham",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":386},"100559548","emus-enhanced-monitoring-using-sensors-after-surgery-100559548","NCT06565559","EMUs: Enhanced Monitoring Using Sensors After Surgery","EMUs","Participant Inclusion Criteria:\n\n* Adults 18 years and older.\n* Undergoing an elective or emergency major surgery procedure with a planned skin incision of 5 cm or greater. Any indication for surgery can exist, including benign, malignant, and trauma.\n* Willing and able to provide written informed consent.\n\nParticipant Exclusion Criteria:\n\n* Those under the age of 18.\n* A documented or suspected allergy to adhesive dressings.\n* Obstetric patients\n* Unwilling or unable to provide written informed consent.",{"count":369,"type":19},1332,"Patients can become critically unwell following surgical operations. Delay in recognition of this deterioration can result in patient harm and even death. Wearable wireless sensors that record patients vital signs such as heart rate could help improve recognition of patient deterioration. The goal of this observational study: Enhanced Monitoring Using Sensors After Surgery (EMUs) is to determine if data from wearable physiological monitors can be used for the early detection of postoperative deterioration, while being acceptable to patients and healthcare staff. The study participants and surgical inpatients undergoing open surgery. There are 3 objectives which each represent a stage of the study:\n\n1. To perform usability testing of device with clinicians, nurses, and healthcare workers in non-clinical environment.\n2. To determine baseline postoperative monitoring practice across our network and perform device usability testing in clinical environment.\n3. To perform a shadow-mode cohort study with collection of time-stamped sensor clinical event data to determine relationships between physiological waveforms and patient deterioration.\n\nThis registration focuses on the shadow-mode cohort study.\n\nParticipants will wear wireless sensors on their chest and fingers, pre-, intra-, and post-operatively for up to 10 days. The sensors will record their vital signs such as heart rate, and oxygen levels. This will then be analysed, and used to aid the design of early detection algorithms that may be able to predict clinical illness or complications in this patient group. This is an observational study gathering real time data only. No changes in patient care will result, and in Stages 2 and 3 no sensor data will be available to clinical teams. This study will be performed in departments of general surgery in Benin, Ghana, Guatemala, India, Mexico, Nigeria, Rwanda, and the United Kingdom.",[372,373],"Surgery","Inpatients",[372,375,376],"Wearable Devices","Global Surgery","2026-02-06",{"date":379,"type":35},"2026-02-10",{"date":381,"type":35},"2024-02-28",{"date":383,"type":19},"2027-07-31",{"name":385,"class":42},"University of Edinburgh",17,{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":396,"conditions":397,"keywords":401,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":415},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.",{"count":43,"type":19},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[398,399,400],"Hypoxemia","Morality","Pneumonia",[402,403,404,405,406],"Health system","Oxygen","Oxygen systems","Oxygen access","Pulse oximetry","2026-02-04",{"date":377,"type":35},{"date":410,"type":35},"2024-07-31",{"date":412,"type":19},"2027-12",{"name":414,"class":42},"Murdoch Childrens Research Institute",6,{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":51,"minAge":423,"maxAge":215,"enrollmentInfo":424,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":438},"100498886","association-of-gestational-cardiovascular-health-with-pregnancy-outcomes-100498886","NCT05776082","Association of Gestational Cardiovascular Health With Pregnancy Outcomes","Association of Cardiovascular Health During Pregnancy With Perinatal Outcomes---a Birth Cohort Study","Inclusion Criteria:\n\n* Maternal age: 20-49 years;\n* Natural conception;\n* Single pregnancy;\n* Plan to have routine prenatal examinations and give birth in the research center;\n\nExclusion Criteria:\n\n* Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy;\n* Assisted reproduction;\n* Multiple pregnancy;\n* Fetus has a known deformity or genetic defects;\n* Incomplete clinical data.","20 Years",{"count":425,"type":19},5000,"Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations. Recently, the American Heart Association proposed the latest cardiovascular health assessment indicator \"Life's Essential 8\". However, there is still a lack of application data for pregnant women. This project intends to explore the application potential of Life's Essential 8 in cardiovascular health assessment of pregnant women and establish appropriate gestaional cardiovascular health standards.",[428],"Pregnant Women","2025-12-21",{"date":431,"type":35},"2025-12-29",{"date":433,"type":35},"2023-03-01",{"date":435,"type":19},"2027-12-31",{"name":437,"class":42},"Women's Hospital School Of Medicine Zhejiang University",3,{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":15,"minAge":447,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":20,"phases":450,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":43},"100512372","phase-3-a-study-to-find-out-if-a-combination-of-3-medicines-for-the-treatment-of-malaria-works-as-well-and-is-as-safe-and-tolerable-as-combinations-of-2-medicines-100512372","NCT05951595","A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combination Therapies (ACTs) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria","FD-TACT","Inclusion Criteria:\n\n* Male or female, aged ≥6 months (no upper limit unless one is required by local regulations) and bodyweight ≥5 kg\n* Ability to take oral medication\n* Fever defined as ≥38°C tympanic temperature or a history of fever within the last 24 hours\n* Acute uncomplicated P. falciparum monoinfection\n* Asexual P. falciparum parasitaemia: 1,000\u002FµL to 250,000\u002FµL determined on a peripheral blood film\n* Written informed consent by the participant, or by the parent\u002Fguardian in case of children lower than the age of consent, and assent if required (per local regulations)\n* Willingness and ability of the participants or parents\u002Fguardians to comply with the study protocol for the duration of the study\n\nExclusion Criteria:\n\n* Signs of severe malaria (adapted from WHO criteria)\n* Patients not fulfilling criteria for severe malaria but with other indication(s) for parenteral antimalarial treatment at the discretion of the treating physician\n* Haemoglobin \\\u003C7 g\u002FdL at screening\n* Participants who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days\n* In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 30 days\n* Acute illness other than malaria requiring systemic treatment\n* Severe acute malnutrition\n* Known HIV, tuberculosis, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other severe infection\n* For women of child-bearing age: pregnant, trying to get pregnant or lactating\n* History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy\n* Previous splenectomy\n* Participation in the previous 3 months and\u002For ongoing follow-up for an interventional study (including FD-TACT)","6 Months",{"count":449,"type":19},1680,[451],"PHASE3","The goal of this open-label randomised, controlled, non-inferiority trial is to assess and compare the efficacy, tolerability and safety of a fixed dose TACT artemether-lumefantrine-amodiaquine (ALAQ) to the ACTs artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) (with single low-dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria in patient. The main question it aims to answer is whether ALAQ, a fixed dose TACT, is as efficacious, safe and tolerable in comparison with AL and ASAQ.\n\nParticipants will be enrolled, admitted and randomised to receive the study drug (ALAQ, AL or ASAQ). Patients will receive directly observed treatments and will be followed up at least once daily for the first 3 days after enrolment followed by weekly visits from D7 up to D42. Patients will be asked to report to the clinics between scheduled visits in case of any illness or other symptoms or complaints.",[454],"Uncomplicated Plasmodium Falciparum Malaria",[456,457,458,459,460],"Artemether","Lumefantrine","Amodiaquine","Artesunate","Triple Artemisinin-based Combination Therapy (TACT)","2025-11-14",{"date":463,"type":35},"2025-11-18",{"date":465,"type":35},"2025-09-11",{"date":467,"type":19},"2026-07-31",{"name":469,"class":42},"University of Oxford",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":158,"sex":15,"minAge":477,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":20,"phases":481,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":119},"100595723","phase-2-a-study-to-assess-the-safety-and-immunogenicity-of-a-vaccine-against-malaria-in-healthy-children-aged-5-60-months-100595723","NCT07036159","A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months","A Phase 2a, Open Label, Randomized, Interventional Study to Assess the Safety and Immunogenicity of Alternative Vaccination Regimens and Reduced Antigen Doses of RTS,S\u002FAS01E Vaccine in Healthy Children Aged 5-60 Months in a Malaria-endemic Area","Inclusion Criteria:\n\n1. Healthy male or female participants aged 5 to 60 months at the time of the first vaccination, who have previously completed the World Health Organization (WHO) Expanded Programme on Immunization (EPI) vaccinations or for younger infants have received all required vaccinations at point of recruitment according to the schedule for the country where the study is conducted.\n2. Participants' parent(s)\u002FLegally Acceptable Representative(s) (LAR), in the opinion of the investigator, can and will comply with the requirements of the protocol (eg, completion of the diaries, returning for follow-up visits).\n3. Written or witnessed\u002Fthumb-printed informed consent obtained from the participant's parent(s)\u002FLAR prior to performance of any study-specific procedure.\n4. Healthy, as established by medical history and clinical examination.\n5. Negative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).\n6. With hemoglobin levels \\>8 g\u002FdL.\n7. Born after a gestation period of ≥37 weeks.\n\nExclusion Criteria:\n\n1. Progressive, unstable, or uncontrolled clinical conditions.\n2. History (known or suspected) of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine.\n3. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n4. Clinical conditions representing a contraindication to IM vaccination or blood draws.\n5. Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.\n6. Recurrent history of or uncontrolled neurological disorders or seizures.\n7. Undernutrition, defined as WHO Z-score less than -2 standard deviation.\n8. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant as a result of participation in the study, for example, any major congenital defects.\n9. Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and medical history.\n10. Administration of long-acting immune-modifying drugs (eg, infliximab) during the study period starting 3 months before the first dose of study vaccine or planned administration during the study period.\n11. Prior receipt of a malaria vaccine (registered or experimental).\n12. Use of any investigational or non-registered product (drug, vaccine, or medical device)\\* other than the study vaccine during the period starting 30 days before the first dose of study vaccine (Day -30 to Day 1), or planned use during the study period.\n\n    \\*Use of herbs and traditional treatments is not considered an exclusion criterion.\n13. Planned administration of a vaccine not foreseen by the study protocol or the country EPI in the period starting 14 days before each dose and ending 28 days after the last dose of study vaccine administration\\*, with the exception of flu vaccines and vaccines administered as part of a public health vaccination campaign\\*.\n\n    \\*If emergency mass vaccination for an unforeseen public health threat (eg, a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided the vaccination is used according to the local governmental recommendations and the Sponsor is notified.\n\n    Under such circumstances, a participant may be considered eligible for study enrollment and\u002For study vaccine administration after the appropriate window for delay has passed, if the participant is confirmed to be eligible after inclusion\u002Fexclusion criteria have been re checked.\n14. Administration of immunoglobulins and\u002For any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.\n15. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine dose or planned administration during the study period. For corticosteroids, this means prednisone ≥0.5 mg\u002Fkg\u002Fday or 20 mg\u002Fday, whichever is the maximum dose for pediatric participants. Inhaled and topical steroids are allowed.\n16. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug or invasive medical device).\n17. Any study personnel's immediate dependents, family, or household members.\n18. Child in care.","5 Months","60 Months",{"count":480,"type":19},238,[482],"PHASE2","The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S\u002FAS01E in healthy children aged 5-60 months in a malaria-endemic area.",[259],[486,487,259,488,489,490],"Parasitic disease","Plasmodium falciparum","Safety","Immunogenicity","Healthy children","2025-09-24",{"date":493,"type":35},"2025-09-29",{"date":495,"type":35},"2025-08-06",{"date":497,"type":19},"2027-04-23",{"name":499,"class":500},"GlaxoSmithKline","INDUSTRY",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":20,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":528},"100483871","phase-3-reducing-mortality-in-adults-with-advanced-hiv-disease-revive-100483871","NCT05580666","Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial","REVIVE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Documented HIV infection\n3. CD4 count criteria:\n\n   i. CD4 count ≤ 100 cells\u002Fmm3 within past 4 weeks; or\n\n   ii. Documented CD4 nadir ≤ 100 cells\u002Fmm3 and complete interruption of ART for ≥ 6 months; or\n\n   iii. Documented CD4 count ≤ 100 cells\u002Fmm3 if ART-naive\n4. Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment\n\nExclusion Criteria:\n\n1. Contraindications to azithromycin:\n\n   i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or\n\n   ii. Personal or family history of QT-prolongation\n2. Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)\n3. Off-label azithromycin prophylaxis or requirement for prolonged (\\> 7 days) azithromycin (or macrolide) therapy",{"count":510,"type":19},8000,[451],"A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.",[514],"HIV Disease Progression",[516,517,518,519],"Human immunodeficiency virus","Antiretroviral therapy","Azithromycin","Mortality","2025-08-26",{"date":522,"type":35},"2025-09-03",{"date":524,"type":35},"2023-05-08",{"date":301,"type":19},{"name":527,"class":42},"Population Health Research Institute",52,{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":20,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":72},"100587766","reducing-deaths-after-surgery-in-low--and-middle-income-countries-a-pilot-cluster-randomised-trial-100587766","NCT06932653","Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial","SurgPASS: Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial","SurgPASS","Inclusion criteria:\n\n* Patients undergoing emergency major abdominal surgery (i.e., midline or non-midline) with an incision greater than or equal to 5cm\n* Patient must not be pregnant\n* Adults only (greater than or equal to 18 years old)\n\nExclusion criteria:\n\n* Minimally invasive surgery\n* Surgery for appendicitis",{"count":217,"type":19},[22],"SurgPASS is a pilot randomised cluster trial utilising a pre-operative checklist with the aim of reducing deaths after surgery. If SurgPASS is successful, the intervention will be implemented in a separate full-scale cluster randomised trial.",[541],"Post-operative Complications",[543,544,545],"pilot","cluster","surgical safety","2025-04-10",{"date":548,"type":35},"2025-04-17",{"date":550,"type":19},"2025-06-01",{"date":552,"type":19},"2026-01-31",{"name":360,"class":42},{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":561,"targetDuration":563,"studyType":55,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":150},"100575570","a-global-prospective-cohort-study-on-outcomes-of-appendicectomy-for-appendicitis-100575570","NCT06774001","A Global Prospective Cohort Study on Outcomes of Appendicectomy for Appendicitis","AlliGatOr","Inclusion Criteria:\n\n* Age: There are no age restrictions, although, if appropriate participating hospitals can choose to only include children or only adults, based on an age cut-off of their choice.\n* Procedure: All patients undergoing appendicectomy for suspected or confirmed appendicitis by any surgical approach should be included. This includes patients who went theatre with suspect appendicitis even if the intraoperative or pathology results found a different diagnosis, so long as an appendicectomy was performed. It also includes patients who went to theatre for reasons other than suspected appendicitis but were found to have appendicitis intraoperatively and underwent appendicectomy. This includes interval appendicectomy and right hemicolectomy if performed for acute appendicitis.\n* Approach: Both open and minimally invasive (laparoscopic and robotic) interventions are eligible for inclusion. Laparoscopic and robotic converted to open cases are also eligible.\n\nExclusion Criteria:\n\n* Indication: Appendicectomy for any indication other than suspected or confirmed appendicitis should be excluded. For example, patients having appendicectomy for known appendiceal neoplasm.\n* Procedure: Patients having appendectomy as part of another surgical procedure should be excluded. For example, patients having removal of appendix as part of a colon cancer procedure are not eligible for inclusion.\n* Approach: Natural orifice surgery and endoscopic treatment for suspected appendicitis are excluded.\n* Previous appendicectomy: Patients having surgery for stump appendicitis are excluded.\n* Return to theatre: Patients should be entered into study only once. A patient returning to theatre after appendectomy should not be re-entered as a new patient.",{"count":562,"type":19},14000,"30 Days","This study aims to assess and improve the global management of appendicitis, the most common emergency surgery, by examining various aspects of emergency care systems worldwide. Appendicitis is a time-sensitive condition, and delays in diagnosis or treatment can lead to complications, affecting patient outcomes and increasing healthcare costs. The study uses appendicitis as a \"tracer condition\" to explore how different healthcare systems manage emergency care, focusing on factors like access, quality, and efficiency. By gathering data from hospitals worldwide, the study seeks to identify areas where emergency surgical care can be improved, particularly in low- and middle-income countries (LMICs).\n\nThe main goal is to identify gaps in emergency care systems, using a set of key performance measures (KPMs) that assess access to care, the quality of surgical treatment, and patient safety. These include factors like the time from symptom onset to first surgical assessment, the rate of appendectomy performed via minimally invasive (laparoscopic) surgery, and postoperative complications. The study aims to collect data on at least 14,000 patients from around 500 hospitals globally between February and May 2025. The data will be analyzed by hospital income group (from low to high) to understand how different resource levels impact outcomes and to help guide future policy and practice improvements.\n\nThe study also includes two sub-studies that focus on specific issues in surgical care. The Sustainability and Waste Management sub-study aims to explore how hospitals manage waste and sustainability practices in operating theatres. This sub-study is part of global efforts to reduce carbon emissions in healthcare settings. The Financing sub-study examines the financial burden of appendicectomy, particularly the out-of-pocket costs for patients in LMICs. It will explore how the costs of open vs. laparoscopic surgery differ and investigate the impact of these costs on patients.\n\nBy combining global data on clinical outcomes with information on hospital resources and patient finances, this study hopes to provide valuable insights into how to improve emergency surgical care across diverse settings, making recommendations that can lead to better access to safe, timely, and affordable treatment for appendicitis worldwide.",[566,567],"Appendicitis","Appendectomy",[569,566,567],"Appendicectomy","2025-03-27",{"date":572,"type":35},"2025-04-02",{"date":574,"type":35},"2025-02-03",{"date":576,"type":19},"2025-12",{"name":360,"class":42},{"id":579,"slug":580,"hasResults":11,"nctId":581,"briefTitle":582,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":158,"sex":15,"minAge":127,"maxAge":585,"enrollmentInfo":586,"targetDuration":4,"studyType":20,"phases":588,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":598,"locationsCount":43},"100584301","mpox-comprehensive-assessment-for-responsive-immunisation-in-emergency-outbreaks-100584301","NCT06887556","Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks","MPOX CARE","Inclusion Criteria:\n\n* Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.\n* Group 1 (suspected exposure cohort) only\n\n  * Live within or adjacent to an epidemiologically identified region of Mpox transmission\n  * Close contacts of those with microbiologically confirmed Mpox\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox\u002FMVA vaccine\n  * Fully recovered from Mpox infection\n* Group 3 (control cohort) only:\n\n  * Asymptomatic with no known exposure to Mpox\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent to take part\n* Unwilling or unable to comply with study procedures\n* History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study\n* Have a bleeding disorder deemed significant by a member of the study team\n* Pregnant or breast-feeding females\n* Group 1 (suspected exposure cohort) only\n\n  * Known history of Mpox infection\n  * Current symptoms consistent with Mpox\n  * Known exposure to Mpox in the last month\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.\n* Group 3 (control cohort only)\n\n  * Symptoms of Mpox\n  * Known exposure to Mpox in the last month","80 Years",{"count":587,"type":19},650,[22],"The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.",[591],"Mpox","2025-03-19",{"date":594,"type":35},"2025-03-20",{"date":596,"type":35},"2025-02-05",{"date":69,"type":19},{"name":360,"class":42},{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":158,"sex":15,"minAge":52,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":20,"phases":609,"briefSummary":610,"conditions":611,"keywords":617,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":72},"100570792","testing-and-comparing-the-impacts-of-mhealth-based-and-web-based-education-on-oral-cancer-100570792","NCT06711848","Testing and Comparing the Impacts of Mhealth-Based and Web-Based Education on Oral Cancer","A Comparative Analysis of the Effectiveness, Usability, Uptake, and Acceptability of an Educational Website and a Mobile Health Application Prototype in Improving Knowledge on Oral Cancer","Inclusion Criteria:\n\n* being a first-year bachelor degree student of either University of Rwanda (Rwanda), University of Peradeniya (Sri Lanka), Usmanu Danfodiyo University (Nigeria), University of Ibadan (Nigeria), or Saveetha University (India)\n* being within the age range of 18 to 39 years\n* having a personal smartphone\n* willingness to participate in the study\n\nExclusion Criteria:\n\n* being a member of staff or a visitor or a non-first year bachelor degree student of University of Rwanda (Rwanda), University of Peradeniya (Sri Lanka), Usmanu Danfodiyo University (Nigeria), University of Ibadan (Nigeria), or Saveetha University (India)\n* being a student of a tertiary institution not selected for the study\n* being below the age of 18 years or above the age of 39 years.\n* not having a personal smartphone\n* not willing to participate in the study","39 Years",{"count":608,"type":19},75,[22],"Introduction: Oral cancer is a malignant neoplastic disease affecting the lip, oral cavity (mouth) and\u002For the oropharynx. Despite the intense and diverse public health interventions on oral cancer prevention, the global prevalence rates of oral cancer and its major risk factors are still very high. Hence, oral cancer is an issue of serious global health importance.\n\nAim: To test and compare the effectiveness, usability, uptake, and acceptability of an educational website and a mobile health application prototype on oral cancer in improving oral cancer knowledge among university students.\n\nMethods: This study will adopt a randomised control trial design, and it will be conducted among 75 first-year bachelor's degree students from five universities across two continents: University of Rwanda (Rwanda, Africa), Usmanu Danfodiyo University (Nigeria, Africa), University of Peradeniya (Sri Lanka, Asia), University of Ibadan (Nigeria), and Saveetha University (India, Aisa). The study participants will be in three groups (Group 1, Group 2, and Group 3). The participants in Group 1 will be the control group (n = 25 participants; 5 participants from each university); that is the group that will not receive an educational intervention. However, those in Group 2 (n = 25 participants; 5 participants from each university) will receive a web-based educational intervention on oral cancer while those in Group 3 (n = 25 participants; 5 participants from each university) will receive an app-based educational intervention on oral cancer. Pretest survey and posttest survey will be done for all participants. The data collected will be statistically analysed using the Statistical Package for Social Sciences (SPSS) version 28 software. Descriptive statistics will be done for all variables while inferential statistics (analysis of variance) will be done to test for associations between variables of interest.\n\nConclusion: The findings of this study will determine the effectiveness, usability, uptake, and acceptability of the tested digital intervention tools.",[612,613,614,615,616],"Oral Cancer","Health Education, Community","Digital Intervention","MHealth Application","MHealth Intervention",[618,619,620,621,622,623,624,625],"mobile health","application","website","impact","knowledge","oral cancer","public health","intervention","2024-11-28",{"date":628,"type":35},"2024-12-02",{"date":630,"type":19},"2025-01-05",{"date":632,"type":19},"2025-04-30",{"name":634,"class":42},"University of Rwanda",{"id":636,"slug":637,"hasResults":11,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":11,"sex":15,"minAge":127,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":20,"phases":645,"briefSummary":646,"conditions":647,"keywords":649,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":150},"100551885","a-stratified-multi-arm-multi-site-randomised-platform-trial-aiming-to-reduce-the-incidence-of-post-operative-ssi-100551885","NCT06465901","A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI","MARLIN: Stratified, Multi-arm, Multi-stage Factorial Randomised Platform Trial Aiming to Reduce the Incidence of Post-operative Surgical Site Infection (SSI).","MARLIN","Inclusion Criteria:\n\n* Patients with at least one abdominal incision that is ≥5cm (open or laparoscopic extraction site), with an anticipated clean-contaminated, contaminated, or dirty surgical wound. Definitions and examples of contamination are given in Table 1.\n* Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) operations.\n* Any operative indication for abdominal surgery (excluding caesarean section; see exclusion criteria).\n* Patient able and willing to provide written informed consent (signature or a fingerprint) prior to surgery (including emergency cases).\n* Patients aged 5 years and over. (This criteria MUST be made country-specific. Each country will decide the lower (and upper, if applicable according to local regulations age limit for the trial. This will be dependent on country-specific regulatory approvals. Age eligibility will vary by country.)\n\nExclusion Criteria:\n\n* Patient unable to complete post-operative follow-up (i.e., will not be contactable after discharge).\n* Patients undergoing clean surgical procedures.\n* Patients undergoing an obstetrics procedure, including caesarean sections.",{"count":644,"type":19},10092,[22],"MARLIN is a stratified, multi-arm, multi-stage factorial randomised platform trial aiming to reduce the incidence of post-operative surgical site infection (SSI).",[648],"Surgical Site Infection",[650,651,652,653],"surgery","global surgery","SSI","surgical site infection","2024-06-18",{"date":656,"type":35},"2024-06-20",{"date":658,"type":19},"2024-09-01",{"date":660,"type":19},"2026-09-30",{"name":360,"class":42},""]